NCT05607342终止早期 1 期
Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate (PORT-MAP)
适应症
干预措施
相关药物
试验速览
- 阶段
- 早期 1 期
- 状态
- 终止
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- To evaluate the effect of Osanetant on the testosterone levels.
研究概览
简要总结
To evaluate the effect of Osanetant on testosterone levels in men with prostate cancer within 28 days of therapy.
详细描述
Primary:
To evaluate the effect of Osanetant on testosterone levels in men with prostate cancer within 28 days of therapy.
Secondary:
- To evaluate the effect Osanetant on pituitary hormones (LH/FSH) and estrogen within 28 days of therapy.
- To evaluate the effect of Osanetant on PSA levels after 28 days (approximately 4 weeks) of therapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Ability of participant OR Legally Authorized Representative (LAR) to understand this study, and participant or LAR willingness to sign a written informed consent
- •Males ≥ 18 years
- •Histologic diagnosis of adenocarcinoma of the prostate (PCa)
- •Planned radical prostatectomy within the study period
- •Testosterone >150ng/ml
- •Adequate organ function, defined as follows: Result Date
- •Leukocytes >1.5K/UL
- •Absolute Neutrophil Count >1.5K/UL
- •NOTE: Patients with established diagnosis of benign neutropenia are eligible to participate with ANC between 1000-1500 if in the opinion of treating physician the trial treatment does not pose excessive risk of infection to the patient.
- •Platelets >100K/UL
- •Hemoglobin ≥ 9 g/dL
- •Serum creatinine ≤ 1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 50 mL/min using the Cockcroft-Gault equation
- •Total bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ 1 x ULN
- •Aspartate aminotransferase and alanine aminotransferase ≤ 2.5 x ULN unless liver metastases are present, in which case they must be ≤ 5 x ULN
- •Men with partners of child-bearing potential must agree to practice sexual abstinence or to use the forms of contraception listed in Child-Bearing Potential/Pregnancy section for the duration of study participation. Men of child-bearing potential must not father a child or donate sperm while receiving investigational treatment. Following treatment (standard of care prostatectomy) there is no further child-bearing potential.
排除标准
- •Current or recent (within 6 months) use of testosterone/estrogen modulating agents (leuprolide, degarelix, bicalutamide, enzalutamide, apalutamide, darolutamide, abiraterone, systemic ketoconazole, tamoxifen, etc)
- •Current use of CYP3A4 inhibitors
- •Subjects using the following medications within 2 weeks prior to first dosing (or within 5 times the half-life of that medication, whichever is longer) will be excluded from the study:
- •Inhibitors of CYP3A4 (including but not limited to macrolide antibiotics, HIV protease inhibitor, azole antifungal drugs, cyclosporine, calcium channel inhibitor, cimetidine)
- •Inducers of CYP3A4 (including but not limited to rifampicin, carbamazepine, efavirenz, bosentan, modafinil, St. John's Wort), Medications with narrow therapeutic index that are metabolized CYP3A4 and/or CYP2D6 are not allowed from screening until up to 5 half-lives after last dose of Osanetant is administered.
- •Cognitive impairment (defined as the presence of diagnosed dementia)
- •Impaired renal function: Cr >1.8
- •Medical history of osteoporosis
- •Current systemic corticosteroid, long-term opioid, spironolactone, or eplerenone use
- •Has a known allergic reaction to any excipient contained in the study drug formulation
- •Active Grade 3 (per the NCI CTCAE, Version 5.0) or higher viral, bacterial, or fungal infection within 2 weeks prior to the first dose of study treatment.
- •Active COVID-19 infection
- •Any history of underlying liver disorder, including hepatitis (see below)
- •Any evidence of acute or chronic hepatitis B or C on screening testing
- •Elevation of any or all liver enzymes (ALT, AST, total bilirubin) above the upper limit of normal (ULN) at baseline testing prior to enrollment
- •A family history of hepatitis or currently living with a person who has been given a diagnosis of hepatitis
- •A history of or currently working as a sex worker
- •A history of or currently using intravenous (IV) drugs
- •A self-reported history of alcoholic dependency or abuse
- •A history of or current diagnosis of cardiovascular disease including heart failure, coronary artery disease, uncontrolled hypertension, uncontrolled diabetes; arrhythmias (or history of), or clinically relevant ECG abnormalities at baseline
研究组 & 干预措施
Pilot Trial: Osanetant 28 Days
Experimental
Pilot Trial: A single dose level (200mg twice daily, oral) will be provided for men with prostate cancer undergoing curative intent surgery. Men will undergo serum testing at baseline, days 2, 3, 7, 14, and 28 as well as 6 weeks post-treatment in order to evaluate efficacy. All men enrolled will be subject to the same study procedures and assessments, regardless of completion of the study protocol, and analysis will occur via intent-to-treat principles.
干预措施: Osanetant (Drug)
结局指标
主要结局
To evaluate the effect of Osanetant on the testosterone levels.
时间窗: 28 days
We will test the ability of Osanetant to suppress testosterone production. A single arm pilot study of Osanetant at 200mg twice daily will be performed. Testosterone levels at baseline will be compared to levels at day 2, 3, 7 ,14, and 28 days of therapy. The overall effect of Osanetant on testosterone levels and the proportion of men achieving castrate levels of testosterone (\<50ng/ml) will be assessed. Additionally, the reversibility of this effect will be assessed by evaluating the testosterone levels at 6-8 weeks posttreatment.
次要结局
- To evaluate the effect of Osanetant on estradiol levels(28 days)
- To evaluate the effect of Osanetant on LH levels.(28 days)
- To evaluate the effect of Osanetant on PSA levels.(28 days)
- To evaluate the effect of Osanetant on FSH levels.(28 days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
A Pilot Study of Parenteral Testosterone and Oral Etoposide as Therapy for Men With Castration Resistant Prostate CancerProstate CancerNCT01084759Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins16
已完成
1 期
Testosterone in Treating Patients With Progressive Prostate Cancer That No Longer Responds to Hormone TherapyProstate CancerNCT00006044Memorial Sloan Kettering Cancer Center
撤回
3 期
Testosterone Effects on Pelvic Floor MusclesUrinary IncontinenceMenopauseNCT04026880Brigham and Women's Hospital
已完成
4 期
Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With HypogonadismHypogonadismNCT01107067Gulhane School of Medicine32
终止
4 期
The Effect of 90-day Oral Testosterone Therapy in Chinese Males With Type 2 Diabetes (T2DM)Assess the Effects of a the 90-day Oral TS Study Regimen on PSA, IPSS, Haemoglobin and Haematocrit, and to Assess Adverse and Serious Adverse Events.NCT01510847Singapore Clinical Research Institute19